Effect of topical cream ,containing Tragacanth on the Eczema and it’s comparison with Mometasone 0.1%

Phase 3

• Conditions: Mild to moderate hand eczema.; Atopic dermatitis

• Registration Number: IRCT20190914044767N1
• Lead Sponsor: Traditional Medicine & Materia Medica Research center Shahid Beheshti university of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 42

Inclusion Criteria

Men and women 18 years or older
One or more eczema lesions in the palm or back area
Mild to moderate plaques
Patients who have not received topical, oral, or injectable medication for the treatment of eczema in the last week (emulsion use is permitted).
Lack of infection or malignancy at the treatment site (no problem with closed wounds).
Patient's consent to participate in the study

Exclusion Criteria

Under 18 years
Pregnancy and lactation
Eczema generalize
Patients with other skin lesions
Taking other topical medicines while participating in the research
Patients taking immunosuppressive systemic drugs or biological drugs.
Infection or skin malignancy at the treatment site

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Atopic dermatitis disease intensity. Timepoint: At the beginning of the study and about 20 days after starting the topical cream (after treatment). Method of measurement: SCORAD Index form.;Duration of recovery. Timepoint: About 20 days after starting the topical cream (after treatment). Method of measurement: Patient Tracking and Evaluation with SCORAD and DLQI.

Secondary Outcome Measures

Name	Time	Method
Quality of dermatology patient's life. Timepoint: At the beginning of the study and about 20 days after starting the topical cream (after treatment). Method of measurement: DLQI questionnaire.